bioihbjkbjnl/mcl2 huggingface dataset:
Cervical Range of Motion and Stretching
Condition: Cervical Shortening
Study type: Interventional

Summary: 
      Cervical range of motion (ROM) is necessary to perform normal activities of daily living and
      deficits are associate with various pathologies. Currently, its unclear if specific
      myofascial stretches will improve cervical range of motion and decrease myofascial
      sensitivity. After a single session of the manual stretching procedure, participants
      immediately demonstrated increased cervical ROM and pressure pain thresholds.
    

Detailed description: 
      Methods: Sixty participants with no history of neck pain or trauma were randomized into one
      of two groups: stretching group (n = 30), or control group (n = 30). The stretching group
      received a standardized manual stretching protocol. The control group did not received
      intervention. Pre and Post-test measurements were recorded for both groups. Within group
      differences and group by time interactions were evaluated for Cervical range of motion ROM
      and myofascial sensitivity. The immediate improvement in active ROM of the cervical spine may
      prompt clinicians to consider the sequencing of treatment. Stretching prior to active
      exercises may allow for active exercise through a larger ROM. Future research is needed to
      evaluate the immediate effects of stretching in the symptomatic population.
    

Intervention name(s): Manual stretching
Intervention type(s): Procedure
Intervention description(s): Manual stretching for the upper trapezius and levator scapulae muscle
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Randomized controlled trial
Masking: Single (Outcomes Assessor)
Primary purpose: Treatment
Keywords: range of motion; muscle sensitivity; muscle stretching
Effects of Surfactants on the Innate Immune System
Condition: Healthy
Study type: Interventional

Summary: 
      In this study we will test the ability of different commercially available hand soaps to
      effect the amount of anti-microbial peptides present on the surface of the human skin after
      washing with these soaps. Based on our experiments on pig skin, we expect the amount of
      antimicrobial peptide expression to decrease after using these different soaps.
    

Detailed description: 
      We will use tape-stripping methods to determine the level of antimicrobial peptides
      (specifically LL-37) present on the human skin after washing with different commercially
      available hand soaps. First we will do a baseline tape-stripping procedure to measure the
      amount of LL-37 on subjects' forearms. Tape stripping involves applying small, round tapes
      (CuDerm, Dallas, TX) to the skin, massaging them for about 10 second, and then removing them.
      This process is repeated 9 times for each tape. After doing baseline tape stripping samples,
      each participant's forearms will be washed with a different soap. The soap will be rinsed
      off, and the skin allowed to dry. After the forearms are dry (about 5 minutes later), repeat
      tape-stripping will be performed. This tape-stripping process will then be repeated 4 hours
      later, and then 24 hours later as well. Results of the LL-37 expression at each time point
      will then be compared between soaps.
    

Intervention name(s): Soap
Intervention type(s): Other
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Health Services Research
Keywords: study; meant; individuals
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
Condition: Leukemia
MeSH terms: Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute
Study type: Observational

Summary: 
      RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
      doctors identify and lean more about biomarkers related to cancer.

      PURPOSE: This research study is studying biomarkers in blood samples from patients with acute
      myeloid leukemia.
    

Detailed description: 
      OBJECTIVES:

      Primary

        -  To determine if serum 2-hydroxyglutarate (2HG) is only detected in acute myeloid
           leukemia (AML) patients with isocitrate dehydrogenase (IDH) mutations.

      Secondary

        -  To determine if the level of serum 2HG impacts leukemia-free survival (LFS).

        -  To determine if the level of serum 2HG impacts overall survival (OS).

        -  To determine if serum 2HG is undetectable at the time of documented clinical remission
           (CR) in IDH-mutated patients.

      OUTLINE: Archived serum samples are analyzed for 2-hydroxyglutarate expression by
      reverse-phase liquid chromatography coupled to mass spectrometry. Results are then compared
      with presence or absence of an IDH mutation, patients' clinical outcome, as well as age, sex,
      white blood cell count at diagnosis, platelet count, bone marrow blast percentage at
      diagnosis, circulating (serum) percentage at diagnosis, cytogenetic risk group, presence of
      FLT3, NPMN1, and/or TET2 mutations, specific IDH mutation, and randomization treatment group
      allocation.
    

Intervention name(s): mutation analysis; protein analysis; laboratory biomarker analysis; liquid chromatography; mass spectrometry
Intervention type(s): Genetic; Genetic; Other; Other; Other
Observational model: Other
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Samples from patients enrolled on E1900 from whom samples were submitted for research
      
Keywords: adult acute myeloid leukemia with 11q23 (MLL) abnormalities; adult acute myeloid leukemia with inv(16)(p13;q22); adult acute myeloid leukemia with t(16;16)(p13;q22); adult acute myeloid leukemia with t(8;21)(q22;q22); untreated adult acute myeloid leukemia; adult acute basophilic leukemia; adult acute eosinophilic leukemia; adult erythroleukemia (M6a); adult pure erythroid leukemia (M6b); adult acute minimally differentiated myeloid leukemia (M0); adult acute monoblastic leukemia (M5a); adult acute monocytic leukemia (M5b); adult acute myeloblastic leukemia with maturation (M2); adult acute myeloblastic leukemia without maturation (M1); adult acute myelomonocytic leukemia (M4)
The Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction in Rural Malawian Children 1-3 Year Olds
Condition: Environmental Enteropathy
MeSH terms: Intestinal Diseases
Study type: Interventional

Summary: 
      To determine if 12 months of legume-based complementary foods is effective in reducing or
      reversing EED and linear growth faltering in a cohort of Malawian children, aged 12-35 months
      to see if these improvements are correlated with specific changes in the enteric microbiome.
    


Intervention name(s): cowpeas complementary food; corn-soy flour; common bean complementary food
Intervention type(s): Dietary Supplement; Dietary Supplement; Dietary Supplement
Intervention description(s): cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.; Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.; common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Investigator)
Primary purpose: Treatment
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Condition: Lung Cancer
MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Study type: Interventional
Phase: Phase 2

Summary: 
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
      docetaxel and gemcitabine hydrochloride, work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab
      together with docetaxel and gemcitabine hydrochloride may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving bevacizumab together with docetaxel
      and gemcitabine hydrochloride works in treating patients with stage IIIB, stage IV, or
      recurrent non-small cell lung cancer.
    

Detailed description: 
      OBJECTIVES:

      Primary

        -  Estimate the 1-year progression-free survival rate in patients with stage IIIB, stage
           IV, or recurrent non-squamous cell non-small cell lung cancer treated with bevacizumab,
           docetaxel, and gemcitabine hydrochloride.

      Secondary

        -  Evaluate the median time to progression in patients treated with this regimen.

        -  Estimate the response rate in patients treated with this regimen.

        -  Determine the median overall survival of patients treated with this regimen.

        -  Determine the incidence of adverse events associated with this regimen in these
           patients.

      OUTLINE: Patients receive bevacizumab IV over 30-90 minutes and docetaxel IV over 60 minutes
      on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats
      every 21 days for up to 6 courses in the absence of disease progression or unacceptable
      toxicity. Patients with responsive or stable disease may then continue to receive bevacizumab
      alone for up to 12 months in the absence of disease progression.

      After completion of study treatment, patients are followed up every 3 months.
    

Intervention name(s): bevacizumab; docetaxel; gemcitabine hydrochloride
Intervention type(s): Biological; Drug; Drug
Intervention description(s): 15 mg/kg on day 1 of a 21-day cycle; 75 mg/m2 on day 1; 900 mg/m2 on days 1, and 8,
Intervention MeSH terms: Bevacizumab; Gemcitabine; Docetaxel
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; adenocarcinoma of the lung; bronchoalveolar cell lung cancer; large cell lung cancer
Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH )
Condition: Anemia, Iron Deficiency; Inflammatory Bowel Diseases
MeSH terms: Intestinal Diseases; Inflammatory Bowel Diseases; Anemia; Anemia, Iron-Deficiency; Iron Deficiencies
Study type: Observational

Summary: 
      The aim of the study is to understand the early experiences of Feraccru® in patients with
      inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA) in the UK, including
      treatment effectiveness, patterns of use and tolerability.
    

Detailed description: 
      The aim of the study is to understand the early experiences of Feraccru® in patients with
      inflammatory bowel disease (IBD) and iron deficiency anaemia (IDA) in the UK, including
      treatment effectiveness, patterns of use and tolerability. By describing the characteristics
      of patients treated with Feraccru® and their outcomes, this study will provide the medical
      community with important information to support treatment decisions for their patients. This
      will ultimately support improvements to patient care, including the long-term outcomes of
      patients with IBD and IDA
    

Observational model: Cohort
Time perspective: Cross-Sectional
Sampling method: Probability Sample
Study population: 
        Real World subjects with IBD (Crohn's disease or ulcerative colitis) who are also diagnosed
        with mild-moderate IDA.
Long-Term Study of MP-214 in Patients With Schizophrenia
Condition: Schizophrenia
MeSH terms: Schizophrenia
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      The objective of this study is to evaluate the long-term safety, tolerability, and efficacy
      of MP-214 in patients with schizophrenia.
    


Intervention name(s): MP-214 3mg; MP-214 6mg; MP-214 9mg; Risperidone 4mg
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).; In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).; In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts 3mg or 6mg of MP-214). In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).; In the double-blind period (before Week 6), participants continue in the same arm they were on in core trial A002-A4. In the open-label period (after Week 6), patients will be rerandomized to 3mg or 6mg of MP-214. After the fourth week of the open-label treatment period, they will be received MP-214 at flexible doses (3mg or 6mg or 9mg).
Intervention MeSH terms: Risperidone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Schizophrenia; Antipsychotic Agents; Mental Disorder; Psychotropic Drugs; Dopamine Agents; Risperidone; Central Nervous System Agents
Analyses of Existing Framingham Data
Condition: Eye Diseases
MeSH terms: Eye Diseases
Study type: Observational

Summary: 
      Since 1948, the Framingham Study has examined a group of men and women every two years for
      the primary purpose of studying the incidence and prevalence of cardiovascular disease and
      its risk factors. In 1971 the Framingham Study began a study of the offspring of the original
      group, including data collection on blood pressure, cigarette smoking, weight, and other
      factors that are of interest to studies of eye disease. Researchers gave eye exams to some of
      the original group and to the offspring group. Data from these eye exams have been used to
      examine risk factors for cataracts, diabetic retinopathy, myopia, and glaucoma.

      The purpose of this study is to use the previously collected data for continued research on
      eye-related disorders. No new eye examinations will be conducted.

      ...
    

Detailed description: 
      We propose to continue to analyze existing Framingham Eye and Heart Study data to identify
      possible risk factors for various eye diseases. Originally begun in 1948 by the National
      Heart, Lung and Blood Institute (NHLBI), the Framingham Heart Study has been examining a
      population-based cohort of men and women biennially since 1948 for the primary purpose of
      studying the incidence and prevalence of cardiovascular disease and its risk factors. In 1971
      the Heart Study began a prospective study of the offspring of the original cohort. The Heart
      Study has collected data on blood pressure, cigarette smoking, weight and many other factors
      of interest for epidemiologic studies of eye disease. Eye examinations were conducted on the
      survivors of the original cohort in a collaborative effort between the NEI and the NHLBI
      between 1973 and 1975 (Framingham Eye Study I; FES I) and then again between 1986 and 1989
      (Framingham Eye Study II; FES II). Eye examinations were conducted on the Offspring Cohort
      from 1989 to 1991 (Framingham Offspring Eye Study; FOES). The Framingham data are unique in
      allowing epidemiologic studies with both cross sectional and longitudinal designs. Over the
      years, data from the Heart Study and the various eye studies have been used to examine
      demographic and risk factor characteristics for cataract, diabetic retinopathy, myopia, and
      glaucoma. To date this collaborative effort has yielded 31 publications by the National Eye
      Institute's Division of Epidemiology and Clinical Research; Rita Hiller is an author of 11.
      This proposal is for the continued use of the previously collected Framingham data. All
      studies will be done in collaboration with Heart Study investigators from Boston University
      which manages the study and conducts annual IRB reviews. No new eye examinations will be
      done.
    

Observational model: Cohort
Time perspective: Retrospective
Keywords: Eye Diseases
Effects of Diaphragmatic and Iliopsoas Myofascial Release in Patients With Chronic Low Back Pain
Condition: Low Back Pain, Recurrent
MeSH terms: Back Pain; Low Back Pain
Study type: Interventional

Summary: 
      The aim of this study is to effectively investigate the relaxation of the diaphragm and
      iliopsoas muscle with myofascial technique in patients with chronic low back pain.
    

Detailed description: 
      Low back pain is a common health problem that can be seen as a symptom and symptom of many
      diseases in the clinic.

      Myofascial release technique is thought to be effective in patients with chronic low back
      pain. Therefore, when the literature is examined, it has been observed that the myofascial
      release technique has studies on pain, range of motion, functionality, muscle stiffness and
      shortness.

      This study will be performed on patients with a total of 42 low back pain. The cases will be
      divided into 2 groups of 21 people by simple random sampling.

      Group 1 (control) will be used with sham diaphragm and iliopsoas muscle myofascial release
      technique and traditional physiotherapy method.

      The second group (experiment) will apply the diaphragm and the myofascial release technique
      of the iliopsoas muscle and the traditional physiotherapy method.

      Patients will be treated for 4 weeks. Traditional physiotherapy method will be applied a
      total of 20 sessions 5 days a week. A total of 12 sessions will be performed, with the
      myofascial release technique of the diaphragm and iliopsoas muscle applied 3 days a week.

      The study focuses on the analysis of the following variables:

      Pain : Numerical Pain Scale

      Joint Range of Motion: Goniometer

      Flexibility: Tape Measure

      Pulmonary Function Test: Spirometer

      Anxiety and Depression: Beck Depression inventory

      Kinesiophobia: Tampa Kinesiophobia Scale

      Disability: Roland-Morris Disability Questionnaire

      The results of these pre-intervention and post-intervention variables will be compared
      between the two groups .
    

Intervention name(s): Experimental: Diaphragmatic and İliopsoas Myofascial Release Techniques; Sham Comparator: Sham Myofascial Release Techniques
Intervention type(s): Other; Other
Intervention description(s): Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.; Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Low Back Pain; Diaphragm; iliopsoas; Myofascial Release
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
Condition: Schizophrenia
MeSH terms: Schizophrenia
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to assess the long-term safety, tolerability and efficacy of
      oral OPC-34712 as monotherapy in adults with schizophrenia.
    

Detailed description: 
      Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the
      world population. Hallucinations and delusions are the most striking characteristic positive
      symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and
      lack of emotion, energy, and motivation) may also be present. The first antipsychotics
      developed for the treatment of schizophrenia were effective against positive symptoms, but
      showed little efficacy for negative symptoms and were also associated with a high incidence
      of side effects. Second generation antipsychotics, represent a significant advancement in the
      treatment of psychotic disorders because they are effective and at the same time exhibit
      fewer side effects than first generation antipsychotics. Although generally safer than first
      generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable
      side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these
      drugs vary considerably.
    

Intervention name(s): OPC-34712
Intervention type(s): Drug
Intervention description(s): Phase A: 1-2 mgs/day by mouth, max of 4 wks.
Phase B: 1-4 mgs/day by mouth, up to 52 weeks
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
A Study to Evaluate the Effects of Manidipine Versus Amlodipine and the Combination of Manidipine Plus Delapril Versus Amlodipine Plus Delapril on Intraglomerular Pressure in Hypertensive Patients
Condition: Hypertension
MeSH terms: Hypertension
Study type: Interventional
Phase: Phase 3

Summary: 
      Eight-week multi-national, multicenter, randomized, double blind, active control, two arms,
      parallel groups study with a 4-week single drug treatment (manidipine or amlodipine) phase
      followed by a 4-week combination treatment (manidipine + delapril or amlodipine + delapril)
      phase.
    

Detailed description: 
      The aim of the current study is to assess the effect of a 4-week single drug treatment with
      manidipine or amlodipine and a 4-week combination treatment with manidipine plus delapril or
      amlodipine plus delapril on intraglomerular pressure in subjects with hypertension.
    

Intervention name(s): amlodipine 10 mg; manidipine 20 mg; amlodipine 5 mg + delapril 30 mg; manidipine 10 mg + delapril 30 mg
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): amlodipine 10 mg once daily; manidipine 20 mg once daily; amlodipine 5 mg + delapril 30 mg once daily; manidipine 10 mg + delapril 30 mg once daily
Intervention MeSH terms: Amlodipine; Manidipine; Delapril
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: hypertension; intraglomerular pressure